Sinonews client, May 30, according to the SASAC public account on the 29th, as of now, Sinopharm China Wuhan Bioproducts Research Institute and Beijing Bioproducts Research Institute of the new crown inactivated vaccine have completed phase I phase II entry In total, more than 2,000 people received vaccines. The existing clinical data shows that the safety and effectiveness of the vaccine have been fully verified, and the incidence and degree of adverse reactions are much lower than those of the various vaccines on the market. It is reported that the clinical trial is divided into three phases, and the completion of phase I-III clinical trials until the market is expected to be at the end of this year or early next year.